Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine and other therapeutics. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a short-wear-time transdermal patch that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone receptor-positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: radiuspharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $22.00 | Neutral | Goldman |
| 5/30/2024 | Sell → Neutral | Seaport Research Partners | |
| 2/28/2024 | $17.50 | Neutral → Sell | Seaport Research Partners |
| 12/14/2023 | Neutral | Seaport Research Partners | |
| 6/8/2022 | $8.00 | Underperform → Neutral | BofA Securities |
| 5/23/2022 | $7.00 | Mkt Perform | SVB Leerink |
| 12/10/2021 | $18.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/10/2021 | $33.00 → $12.00 | Buy → Neutral | Goldman Sachs |
| 12/9/2021 | $30.00 → $20.00 | Market Perform | SVB Leerink |
| 12/9/2021 | $23.00 → $10.00 | Neutral | HC Wainwright & Co. |
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
4 - RADIUS RECYCLING, INC. (0000912603) (Issuer)
Goldman initiated coverage of Radius Recycling with a rating of Neutral and set a new price target of $22.00
Seaport Research Partners upgraded Radius Recycling from Sell to Neutral
Seaport Research Partners downgraded Radius Recycling from Neutral to Sell and set a new price target of $17.50
Seaport Research Partners initiated coverage of Radius Recycling with a rating of Neutral
BofA Securities upgraded Radius Health from Underperform to Neutral and set a new price target of $8.00
SVB Leerink initiated coverage of Radius Health with a rating of Mkt Perform and set a new price target of $7.00
Morgan Stanley downgraded Radius Health from Equal-Weight to Underweight and set a new price target of $7.00 from $18.00 previously
Goldman Sachs downgraded Radius Health from Buy to Neutral and set a new price target of $12.00 from $33.00 previously
SVB Leerink reiterated coverage of Radius Health with a rating of Market Perform and set a new price target of $20.00 from $30.00 previously
HC Wainwright & Co. reiterated coverage of Radius Health with a rating of Neutral and set a new price target of $10.00 from $23.00 previously
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
SCHEDULE 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
8-K - RADIUS RECYCLING, INC. (0000912603) (Filer)
SD - RADIUS RECYCLING, INC. (0000912603) (Filer)
DEFM14A - RADIUS RECYCLING, INC. (0000912603) (Filer)
SCHEDULE 13G/A - RADIUS RECYCLING, INC. (0000912603) (Subject)
SCHEDULE 13G - RADIUS RECYCLING, INC. (0000912603) (Subject)
PREM14A - RADIUS RECYCLING, INC. (0000912603) (Filer)
10-Q - RADIUS RECYCLING, INC. (0000912603) (Filer)